Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Meeting Highlights
Meeting Highlights
ESMO Highlights
Efficacy and Safety of Front-Line Veliparib and Paclitaxel Weekly versus Every 3 Weeks in the VELIA Study
Read More
Meeting Highlights
AACR Highlights
Atezolizumab, Vemurafenib, and Cobimetinib Triplet Therapy Improves PFS in BRAF-Positive Melanoma
Phoebe Starr
Read More
Meeting Highlights
AACR Highlights
Two Ways to Target Tumors with KRAS Mutations
Wayne Kuznar
Read More
Meeting Highlights
ASCO Highlights
ASCO 2020 Lung Cancer Highlights
Read More
Meeting Highlights
ASCO Highlights
Clinical Activity of the RET Inhibitor Pralsetinib (BLU-667) in Patients with RET-Altered Solid Tumors
Read More
Meeting Highlights
ASCO Highlights
Clinical Activity of Pralsetinib (BLU-667) in Patients with Advanced RET Fusion–Positive NSCLC
Read More
Meeting Highlights
ASCO Highlights
AcceleRET Lung: A Phase 3 Study of Pralsetinib in Patients with RET Fusion–Positive Metastatic NSCLC
Read More
Meeting Highlights
ASCO Highlights
Efficacy of Capmatinib in Second-Line Treatment of Patients with METex14-Mutated NSCLC
Read More
Meeting Highlights
ASCO Highlights
Efficacy and Safety of Entrectinib in Patients with NTRK Fusion–Positive Solid Tumors
Read More
Meeting Highlights
ASCO Highlights
Next-Generation RET Inhibitor TPX-0046 Is Active in Drug-Resistant and Naïve RET-Driven Cancer Models
Read More
6
7
8
9
10
11
12
Page 9 of 17
Results 81 - 90 of 169